The Cancer Research Institute will bestow its highest honors on three scientists who have made fundamental contributions to the fields of immunology and cancer immunotherapy at its annual taking place on Thursday, October 25, 2018, at The Metropolitan Club in New York City.
he Cancer Research Institute will honor biotechnology company Regeneron, and journalist and filmmaker Perri Peltz with the 2018 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research at its annual gala taking place on Thursday, October 25, 2018, at The Metropolitan Club in New York City.
A clinical trial to evaluate the combination of ONCOS-102, an experimental anti-tumor virotherapy, with the checkpoint blockade antibody IMFINZI® (durvalumab) for advanced ovarian and colorectal cancers has been initiated.
Newly published report in Nature Reviews Drug Discovery that provides a comprehensive, independent analysis of the global landscape of cancer cell therapies, including all agents from preclinical to post-market stages.
Month-long awareness and education campaign in June highlighting breakthroughs in cancer treatment with immunotherapy and the urgent need for more research funding
Cancer Research Institute iAtlas now online -- a comprehensive web-based tool that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvironment.
On March 19-20 in California, the third Fortune Brainstorm HEALTH conference brought together renowned leaders from healthcare and related industries to provide insight into today’s most pressing challenges as well as how we might solve them.
Comprehensive immuno-oncology landscape analysis conducted by nonprofit Cancer Research Institute quantifies global development of immunotherapy and identifies opportunities to advance the field to improve patient care
Fight Colorectal Cancer (Fight CRC) and the Cancer Research Institute (CRI) are proud to announce “A Blueprint to Advance Colorectal Cancer Immunotherapies”
The Cancer Research Institute will give awards for scientific achievements in immunology and tumor immunology and immunotherapy to three accomplished research scientists at its 31st Annual Awards Dinner on November 14, 2017, in New York City.
Cancer Research Institute will recognize Genentech and Bruce Ratner for their contributions to medical research, patient care, or public education in the fields of cancer immunology and immunotherapy.
A collaborative campaign brings together the leading funder of immunotherapy research internationally with North America’s largest nonprofit dedicated to supporting Israeli cancer research
$400k grant to Johns Hopkins University School of Medicine investigator Cynthia Sears will carry out research aimed at improving effectiveness of immunotherapy in patients with colorectal cancer.
$1 million CRI Technology Impact Award will support UPENN investigator's development of microchip-based research models that mimic human cancer and immune cell interactions
CRI's 2017 Immunotherapy Patient Summit Series will travel to five U.S. cities to provide free educational programming designed for cancer patients and caregivers who are seeking to learn more about cancer immunotherapy and clinical trials.
data from four early-phase immunotherapy combination trials will be presented at the American Society for Clinical Oncology (ASCO) Annual meeting in Chicago on June 5, 2017.
Over the past few years, checkpoint blockade immunotherapies have revolutionized cancer treatment and helped many patients who were previously considered untreatable. Now, discoveries made by two Cancer Research Institute scientists could help make these and other immunotherapies even more transformative for patients.
This Saturday [Dec 3], the 58th Annual Meeting of the American Society of Hematology will begin in San Diego, where the latest advances in research for blood cancers including leukemia, lymphoma, and myeloma will be highlighted during the four days of talks and poster presentations.
Nonprofit devoted to cancer immunotherapy will honor the biotech company Amgen for its contributions to cancer immunotherapy treatment and patient education
Media are encouraged to register to attend the second annual International Cancer Immunotherapy Conference organized by the Cancer Research Institute, Association for Cancer Immunotherapy, European Academy of Tumor Immunology, and the American Association for Cancer Research.
Announcement of winners of the 2016 William B. Coley and Frederick W. Alt Awards, celebrating key scientific contributions to the fields of immunology, tumor immunology (also known as immuno-oncology), and cancer immunotherapy.
Month-long educational and awareness initiative designed increase public awareness of the potential of cancer immunotherapy to treat and potentially cure all cancers.
One-day, multi-distance ride through the Lower Hudson Valley’s breathtaking landscape to raise funds for the nonprofit Cancer Research Institute and increase awareness of the potential of immunotherapy to cure all cancers.
Immunotherapy is currently revolutionizing cancer treatment and, according to Axel Hoos, M.D., Ph.D., has the potential to improve patient outcomes significantly in the future. Dr. Hoos leads one of the Cancer Research Institute’s (CRI) programs—the Cancer Immunotherapy Consortium (CIC)—that played an important role in enabling early immunotherapy trials to succeed. In a paper published in Nature Reviews last week, he laid out the current immunotherapy development paradigm, as well as his strategic vision to optimize the implementation of next generation immunotherapies.
New hope now exists for patients with advanced kidney cancer. Yesterday, the FDA approved the immunotherapy drug nivolumab (Opdivo®, Bristol-Myers Squibb) to treat metastatic renal cell carcinoma (RCC)—the most common form of kidney cancer—that has failed to respond to a previous treatment. This breakthrough can be traced all the way back to the research of scientists funded by the Cancer Research Institute (CRI).
Targovax, a biotechnology company based in Oslo, has partnered with two nonprofit cancer research organizations to test its virotherapy product in early-phase combination clinical trials.
Cancer Research Institute (CRI) is proud to announce that it will be participating in the Revlon LOVE IS ON Million Dollar Challenge, which runs now through October 29, 2015.
The Cancer Research Institute announced today the winners of the 2015 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research. This annual award recognizes the contributions of individuals, corporations, and foundations that have made a significant impact on medical research, patient care, or public education in the fields of cancer immunology and immunotherapy.
The Cancer Research Institute will bestow its highest honors on three scientists who have made fundamental contributions to the fields of immunology and cancer immunotherapy. The award ceremony will take place at the Institute’s 29th Annual Awards Dinner on Wednesday, September 17, 2015, at The Metropolitan Club in New York City.
The Cancer Research Institute (CRI), a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.
"Immunotherapy: 5 Ways to Stop Cancer" features five 1-minute animated videos that provide a quick overview of the five most common immunotherapies in use: monoclonal antibodies, checkpoint inhibitors, cancer vaccines, adoptive cell therapy, and oncolytic viruses.
Cancer immunotherapy, which is designed to empower a patient’s own immune system to eliminate cancer cells anywhere in the body, has produced cure-like remissions in very advanced cancers, including melanoma, lung cancer, and leukemia.
The Cancer Research Institute (CRI) is proud to announce the addition of peer-to-peer advocacy, enhanced sharing functionality, and tumor type-specific information to TheAnswerToCancer.org (TheA2C), a first-of-its-kind website and online community devoted specifically to cancer immunotherapy.
The Cancer Research Institute (CRI) will host its 22nd Annual International Cancer Immunotherapy Symposium October 6-8, 2014, at The Grand Hyatt in New York City.
CRI honors four scientists for their collective contributions to the discovery and elucidation of the PD-1 receptor pathway as a therapeutic target in cancer treatment.
Immudex has entered into a strategic agreement with the US Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute, and the European Association for Cancer Immunotherapy (CIMT), under which Immudex will provide MHC-peptide multimer and Elispot proficiency panel services worldwide.